Is SLRX or QYLD a better dividend investment in 2026?

SLRX currently yields 238.10% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: SLRX offers higher current income.

What is the dividend yield difference between SLRX and QYLD?

SLRX has a forward dividend yield of 238.10% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 226.18 percentage points.

Home › Compare › SLRX vs QYLD

SLRX vs QYLD: Dividend Comparison 2026

SLRX yields 238.10% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SLRX wins by $339.57M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SLRX

● Live price

238.10%

Share price

$0.84

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$339.60M

Annual income

$185,958,933.65

Full SLRX calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — SLRX vs QYLD

📍 SLRX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SLRX	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SLRX + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SLRX pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLRX

Annual income on $10K today (after 15% tax)

$20,238.10/yr

After 10yr DRIP, annual income (after tax)

$158,065,093.60/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, SLRX beats the other by $158,060,283.19/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLRX + QYLD for your $10,000?

SLRX: 50%QYLD: 50%

100% QYLD50/50100% SLRX

Portfolio after 10yr

$169.81M

Annual income

$92,982,296.48/yr

Blended yield

54.76%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on SLRX right now

SLRX

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-14.5

Piotroski

3/9

QYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLRX buys

QYLD buys

No recent congressional trades found for SLRX or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSLRXQYLD

Forward yield	238.10% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$339.60M ✓	$25.4K
Annual income after 10y	$185,958,933.65 ✓	$5,659.31
Total dividends collected	$322.91M ✓	$27.1K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: SLRX vs QYLD ($10,000, DRIP)

Year	SLRX Portfolio	SLRX Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$34,510	$23,809.52	$10,352	$1,192.36	+$24.2K → SLRX
2	$113,715	$76,790.22	$10,830	$1,347.57	+$102.9K → SLRX
3	$358,160	$236,484.38	$11,460	$1,539.07	+$346.7K → SLRX
4	$1,079,339	$696,107.48	$12,275	$1,777.84	+$1.07M → SLRX
5	$3,115,421	$1,960,529.07	$13,323	$2,078.95	+$3.10M → SLRX
6	$8,622,197	$5,288,696.04	$14,667	$2,463.34	+$8.61M → SLRX
7	$22,905,117	$13,679,366.22	$16,396	$2,960.57	+$22.89M → SLRX
8	$58,470,750	$33,962,275.23	$18,631	$3,612.97	+$58.45M → SLRX
9	$143,588,724	$81,025,021.41	$21,548	$4,482.15	+$143.57M → SLRX
10	$339,598,869	$185,958,933.65	$25,398	$5,659.31	+$339.57M → SLRX

SLRX vs QYLD: Complete Analysis 2026

SLRX — Stock

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Full SLRX Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this SLRX vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLRX vs SCHD SLRX vs JEPI SLRX vs O SLRX vs KO SLRX vs MAIN SLRX vs XYLD SLRX vs JEPQ SLRX vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.